Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Clinical Physiology of the Kidneys
-
27 min
1. Molecular basis of genetic renal diseases 1- Dr. Paul Jennings
-
25 min
2. Molecular basis of genetic renal diseases 2- Dr. Paul Jennings
-
36 min
3. Assessment of renal function- Dr. Jochen Raimann
-
30 min
4. Isolated microhematuria and proteinuria in adults- Dr. Eva Seiringer
-
19 min
5. Intradialytic oxygen saturation- Dr. Lili Chan
-
28 min
6. Pervasive sensing in chronic kidney disease- Ms. Maggie Han
- Ms. Schantel Williams
-
52 min
7. The genetic basis of kidney cancer- Dr. W. Marston Linehan
- Glomerular Disorders
-
38 min
8. Focal segmental glomerulosclerosis- Prof. Moin Saleem
- Tubular Interstitial Disorders
-
23 min
9. What’s new for IgA nephropathy part 1: epidemiology and pathogenesis- Prof. Maurizio Salvadori
-
23 min
10. What’s new for IgA nephropathy part 2: clinical presentation, diagnosis, prognosis, treatment- Prof. Maurizio Salvadori
-
31 min
11. Renal complications of sickle cell disease- Dr. Claire Sharpe
- Acute Kidney Injury
-
30 min
- Chronic Kidney Disease
-
24 min
13. Pathophysiology of acute renal failure- Dr. Viviane Calice-Silva
-
29 min
14. Anaemia in chronic kidney disease- Prof. Iain Macdougall
-
41 min
15. Kidney disease and pregnancy: a new era?- Dr. Kate Bramham
- Renal Cell Carcinoma
-
47 min
16. The genetics and genomics of familial renal carcinoma- Prof. Eamonn Maher
-
58 min
17. Immune checkpoint blockade in renal cell carcinoma- Prof. David McDermott
- Pharmacology and the Kidney
-
30 min
-
62 min
19. Toxicology of the kidney- Prof. Lawrence Lash
- Proteomics and the Kidney
-
40 min
20. Proteomics in diabetic kidney disease- Prof. Peter Rossing
-
53 min
21. Urinary proteomics in kidney and cardiovascular disease- Prof. Harald Mischak
- Pediatric Nephrology
-
45 min
22. Continuous renal replacement therapy (CRRT) in children- Prof. Timothy E. Bunchman
- Archived Lectures *These may not cover the latest advances in the field
-
38 min
23. Proteomics in kidney disease: clinical considerations- Prof. Peter Rossing
Printable Handouts
Navigable Slide Index
- Introduction
- Agenda
- Proteomics: definition
- Discovery of new markers
- Proteomic utility in DN (Diabetic Nephropathy)
- Albuminuria and mortality in DM individuals
- RENAAL trial
- Early intervention?
- Natural history of diabetic nephropathy
- U-albumin
- Hypothesis driven search for new biomarkers
- Growth differentiation factor 15
- Multimarker proteomic techniques
- Plasma proteomic analysis
- Plasma proteome analysis of T1D patients
- Network analysis on the case control ratio
- Kininogen and kininogen fragments as markers
- Erk 1/2 phosphorylation in tubular cell lines
- CDK prediction post liver transplantation (1)
- CDK prediction post liver transplantation (2)
- Urine proteomic profiling
- CE-MS proteomic technique
- Proteomics technology platform
- Individual analyses to compiled patterns
- Individual analyses to compiled patterns: Example
- Proteomic CKD biomarker discovery
- CKD-biomarkers: collagen
- CKD-biomarkers: apoptosis related proteins
- Pathophysiological suggestions
- Proteomic profile of T1DM with or without DN
- Candesartan in T2DM and DN
- Prediction analysis
- Urinary protein profiles of ADPKD patients
- Urinary proteomics in Fabry and controls
- Profiles of ERT treated female Fabry patients
- Marker implementation
- Systems biology in CKD
- Conclusions
- Perspectives
- Priority EU project
- Priority EU project in details
- Thank you for listening
- Acknowledgements
Topics Covered
- Proteomics for clinical use
- Available and applied single risk marker strategies in nephrology based on hypothesis driven biomarker search
- Open or unbiased multimarker approaches including plasma and urine proteomics
- Examples from different renal diseases
- Data from cross sectional and longitudinal studies
- Proteomics may provide insight into disease pathology
- Proteomics may provide risk stratification for clinical trials
- Example: intervention trial for type 2 diabetic subjects with high risk urinary proteomic pattern
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Rossing, P. (2013, November 5). Proteomics in kidney disease: clinical considerations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 26, 2024, from https://hstalks.com/bs/2656/.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Rossing has received the following: Consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi Aventis, Research grants from AstraZeneca Bayer and Novo Nordisk.
